Srinivas Akkaraju, Director of Alumis, purchased 588,235 shares at $17.00 per share, totaling ~$10.0 million on Jan. 9, 2026. This transaction represented a significant increase in indirect holdings by nearly 47%, following a strong one-year stock appreciation of +206.29% as of Jan. 16, 2026.

The acquisition of these shares by Akkaraju through Samsara Opportunity Fund, L.P. marks a strategic move to rapidly build exposure as capacity allows, with all shares held indirectly post-transaction. The trade price of $17.00 per share reflects a favorable entry compared to recent market levels, indicating a bullish stance on the stock’s potential.

Alumis, a clinical-stage biotechnology company, focuses on developing therapies for autoimmune and neuroinflammatory diseases through advanced TYK2 inhibitor technology. Recent successful phase 3 trials with envudeucitinib show promise for psoriasis treatment, outperforming competitors like Otezla. The stock has surged over 400% in the past three months, aligning with Akkaraju’s bullish outlook.

Read more at Yahoo Finance: An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million